Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Tengteng Yu, Mu Hao, Hailin Chen, Kenneth Wen, Tingjian Wang, Thomas C.M Smits, Mehmet K. Samur, Eugenio Morelli, Lijie Xing, Liang Lin, Jun Qi, Gang An, Nikhil C Munshi, Yu-Tzu Tai, Lugui Qiu, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 854–855.

https://doi.org/10.1182/blood-2022-159137

Published: 2022

Journal Articles

Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation

Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Mike Daley, Haihui Lu, Adwait Oka, Joni Lam, Nikhil C Munshi, Kenneth C. Anderson, Yu-Tzu Tai

Blood (2022) 140 (Supplement 1): 9968–9969.

https://doi.org/10.1182/blood-2022-155553

Published: 2022

Journal Articles

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136824

Published: 2020

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

Journal Articles

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Lijie Xing, MD, Yuyin Li, PhD, Liang Lin, PhD, Tengteng Yu, MD PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3096.

https://doi.org/10.1182/blood-2019-127135

Published: 2019

Journal Articles

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Gang An, MD, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3105.

https://doi.org/10.1182/blood-2019-130927

Published: 2019

Journal Articles

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Kenneth Wen, Tengteng Yu, MD PhD, Phillip A Hsieh, Yuyin Li, PhD, Nikhil C. Munshi, MD, Joachim Wahl, PhD, Katja Matthes, Kenneth C. Anderson, MD, Tara Chapman-Arvedson, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 135.

https://doi.org/10.1182/blood-2019-128528

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Yuyin Li, PhD, Liang Lin, PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Tengteng Yu, MD PhD, Gang An, Lugui Qiu, MD PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4381.

https://doi.org/10.1182/blood-2019-130297

Published: 2019

Journal Articles

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

Yan Xu, MD, Matthew Ho, PhD, Mehmet Kemal Samur, PhD, Kenneth Wen, Shuhui Deng, MD, Lanting Liu, MD, Tengteng Yu, MD PhD, Zuzana Chyra, PhD, Sanika Derebail, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 5539.

https://doi.org/10.1182/blood-2019-130902

Published: 2019

Journal Articles

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Yu-Tzu Tai, PhD, John Dulos, PhD, Lars Guelen, Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip A Hsieh, Peter van Zandvoort, Bsc, Guido van de Wiel, Jos van de Crommert, Bsc, Bonny Lejeune, Hamid Namini, Hans Eenennaam, PhD, Andrea van Elsas, PhD, Paul Richardson, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2018-99-117296

Published: 2018

Journal Articles

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Blood (2018) 132 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2018-99-118994

Published: 2018

Journal Articles

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip Hsieh, Gang An, MD, Lugui Qiu, MD PhD, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 407.

https://doi.org/10.1182/blood-2018-99-110317

Published: 2018

Journal Articles

An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma

Tengteng Yu, MD, Lijie Xing, MD, Liang Lin, PhD, Jiye Liu, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip Hsieh, James Myette, Bharat Chaganty, Hedy Adari, Hamid Tissire, Ketan Deotale, Zach Shriver, Nikhil Munshi, MD, Yu-Tzu Tai, PhD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 5617.

https://doi.org/10.1182/blood-2018-99-119112

Published: 2018

Journal Articles

Anti-BCMA BiTE ® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Shih-Feng Cho, MD PhD, Liang Lin, PhD, Lijie Xing, MD, Jiye Liu, PhD, Tengteng Yu, MD, Kenneth Wen, BS, Phillip Hsieh, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 592.

https://doi.org/10.1182/blood-2018-99-118425

Published: 2018

Journal Articles

Primary Plasma Cell Leukemia in China: A Retrospective Single Center Study

Tengteng Yu, Yan Xu, MD, An Gang, MD, Zengjun Li, Mu Hao, PhD, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5428.

https://doi.org/10.1182/blood.V130.Suppl_1.5428.5428

Published: 2017

Journal Articles

AURKA Regulates the Mechanism of ATR Mediated DNA Damage Response about Drug Resistance in Multiple Myeloma

Zhang Shuaishuai, MD, Yu Qin, An Gang, MD, Mu Hao, PhD, Yan Xu, MD, Shuhui Deng, Tengteng Yu, Wen Zhou, Lugui Qiu, MD

Blood (2017) 130 (Supplement 1): 5354.

https://doi.org/10.1182/blood.V130.Suppl_1.5354.5354

Published: 2017

Journal Articles

PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma

Tengteng Yu, MD, Lanting Liu, Shuaishuai Zhang, MD, Mu Hao, MD,PhD, Lugui Qiu, MD

Blood (2016) 128 (22): 4495.

https://doi.org/10.1182/blood.V128.22.4495.4495

Published: 2016

NARROW

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Impacts of a Proliferation-Inducing Ligand on Current Therapeutic Monoclonal Antibody-Induced Cytotoxicity Against Human Multiple Myeloma Cells

AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma

Anti-BCMA BiTE ® AMG 701 Potently Induces Specific T Cell Lysis of Human Multiple Myeloma (MM) Cells and Immunomodulation in the Bone Marrow Microenvironment

Primary Plasma Cell Leukemia in China: A Retrospective Single Center Study

AURKA Regulates the Mechanism of ATR Mediated DNA Damage Response about Drug Resistance in Multiple Myeloma

PHF19 Promotes Drug Resistance through EZH2 Inactivation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only